- Home
- FRO vs RYTM Comparison
FRO vs RYTM Comparison
Compare FRO & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FRO
- RYTM
- Stock Information
- Founded
- FRO 1985
- RYTM 2008
- Country
- FRO Cyprus
- RYTM United States
- Employees
- FRO N/A
- RYTM N/A
- Industry
- FRO Marine Transportation
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- FRO Consumer Discretionary
- RYTM Health Care
- Exchange
- FRO Nasdaq
- RYTM Nasdaq
- Market Cap
- FRO 4.0B
- RYTM 4.3B
- IPO Year
- FRO N/A
- RYTM 2017
- Fundamental
- Price
- FRO $18.97
- RYTM $86.70
- Analyst Decision
- FRO Strong Buy
- RYTM Strong Buy
- Analyst Count
- FRO 3
- RYTM 13
- Target Price
- FRO $23.33
- RYTM $88.77
- AVG Volume (30 Days)
- FRO 3.4M
- RYTM 948.9K
- Earning Date
- FRO 08-29-2025
- RYTM 08-05-2025
- Dividend Yield
- FRO 9.33%
- RYTM N/A
- EPS Growth
- FRO N/A
- RYTM N/A
- EPS
- FRO 1.56
- RYTM N/A
- Revenue
- FRO $1,899,854,000.00
- RYTM $136,863,000.00
- Revenue This Year
- FRO N/A
- RYTM $37.56
- Revenue Next Year
- FRO $18.09
- RYTM $74.99
- P/E Ratio
- FRO $11.80
- RYTM N/A
- Revenue Growth
- FRO 0.88
- RYTM 48.88
- 52 Week Low
- FRO $12.40
- RYTM $40.61
- 52 Week High
- FRO $25.68
- RYTM $94.80
- Technical
- Relative Strength Index (RSI)
- FRO 58.32
- RYTM 76.93
- Support Level
- FRO $17.72
- RYTM $64.65
- Resistance Level
- FRO $18.67
- RYTM $94.80
- Average True Range (ATR)
- FRO 0.54
- RYTM 3.47
- MACD
- FRO 0.10
- RYTM 2.75
- Stochastic Oscillator
- FRO 80.24
- RYTM 76.18
About FRO Frontline Plc
Frontline PLC is an international shipping company engaged in the seaborne transportation of crude oil and oil products. Group operates through the tankers segment. The tankers segment includes crude oil tankers and product tankers. Its geographical area of operation includes Arabian Gulf, West African, the North Sea, and the Caribbean. Frontline earns revenue through voyage charters, time charters, and a finance lease. It is also involved in the charter, purchase, and sale of vessels.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its lead asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.